Citations

Clear

2429 citation(s) found for "Shah, SS".

A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia
Thompson, Meghan, Mato, Anthony, Palomba, Lia, Leslie, Lori, Derkach, Andriy, Nemirovsky, David, Islam, Prioty, Geyer, Mark, Caron, Philip, Goldberg, Aaron, Kumar, Anita, Moskowitz, Alison, Lue, Jennifer, Owens, Colette, Salles, Gilles, Stein, Eytan, Steiner, Raphael, Torka, Pallawi, Dahncke, Lori, Ordona, Emily, Meem, Mashiyate, Hutzler, Claire, Harris, Miranda, Shah, Monica, Karnam, Megha, Nogan, Lauren, Maloney, Caitlin, Shah, Anmol, Nyima, Tenzin, Dorsey, Colleen, Doyle, Kate, Howgate-Klingaman, Jennifer, Brutus, Jamila, Tyznar, Dianna, Lincke, Anna, Wray, Rick, Feldman, Tatyana, Zelenetz, Andrew, Roeker, Lindsey, Thompson, Meghan, Mato, Anthony, Palomba, Lia, Leslie, Lori, Derkach, Andriy, Nemirovsky, David, Islam, Prioty, Geyer, Mark, Caron, Philip, Goldberg, Aaron, Kumar, Anita, Moskowitz, Alison, Lue, Jennifer, Owens, Colette, Salles, Gilles , Stein, Eytan, Steiner, Raphael, Torka, Pallawi, Dahncke, Lori, Ordona, Emily, Meem, Mashiyate, Hutzler, Claire, Harris, Miranda, Shah, Monica, Karnam, Megha, Nogan, Lauren, Maloney, Caitlin, Shah, Anmol, Nyima, Tenzin, Dorsey, Colleen, Doyle, Kate, Howgate-Klingaman, Jennifer, Brutus, Jamila, Tyznar, Dianna, Lincke, Anna, Wray, Rick, Feldman, Tatyana, Zelenetz, Andrew, Roeker, Lindsey

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5676-5676

10.1182/blood-2025-5676 Get It

Abstract Background: Advantages of covalent Bruton Tyrosine Kinase inhibitor (cBTKi) treatment (tx), as compared to BCL2 inhibitor (BCL2i) containing regimens, include ease of initial administration without a requirement for frequent laboratory monitoring, even in patients (pts) with bulky disease. However, limitations of cBTKi monotherapy include acquired resistance, cumulative toxicity and the financial burden associated with continuous administration. CLL pts treated on the E1912 study who discontinued (dc) ibrutinib for reasons other than progression of disease (PD) had a median progression free survival (PFS) of ~2.7 years from ibrutinib dc, suggesting that a time-limited cBTKi strategy may be feasible for some pts(Shanafelt et al. Blood Advances 2025). We hypothesized that acalabrutinib (acala) and obinutuzumab (O) could be administered as a time-limited initial tx for CLL with duration guided by minimal residual disease (MRD). Methods: This is an ongoing phase II, multicenter, investigator-initiated study of acala and O for previously untx pts with CLL/small lymphocytic lymphoma (SLL) requiring tx per iwCLL 2018 criteria (NCT04722172). Pts with TP53 aberrancy are excluded. Pts receive acala 100 mg twice daily and O during 28-day cycles (C) 2-7. Undetectable MRD is defined with a 10-4 sensitivity in the peripheral blood (PB) by ClonoSeq next generation sequencing (uMRD4). Pts undergo MRD testing at C13; if uMRD4 at C13 with a complete response (CR) or partial response (PR), pts dc acala and enter tx free observation (TFO). If detectable MRD4 (dMRD4) at C13, pts continue acala until uMRD4, with repeat MRD testing occurring at C16, 19, 22 and 25. All pts dc acala after a maximum of 26C and enter TFO, even if dMRD4. If pts have PD meeting iwCLL criteria for tx during TFO, re-tx consists of acala + 6 cycles of O. Pts are followed for 13C of re-tx. Primary endpoint is 36-month PFS. Results: 55 pts initiated tx. Baseline characteristics include: median age 67, 64% male, 47% LN ≥ 5 cm, 73% IGHV unmutated. Best overall response rate (ORR) was 95% (CR: 4, PR: 48, SD: 0, PD: 1, unknown: 2). Best uMRD4 rate at any time during the study was 49% (n=27 pts, intention-to-treat, IIT). 5 pts dc tx prior to C13 MRD testing (2 pt decision, 2 AE, 1 due to PD after ~4C). At C13, 22 pts (40% of IIT) were uMRD4; 21 entered TFO after 13C and 1 pt had 19C tx prior to TFO. 28 pts had dMRD4 (51% ITT) at C13. Between C13 and 26, 2 pts became uMRD4 and entered TFO, 1 pt died (COVID-19), and 2 pts stopped acala for tx of other cancers. 21 pts completed 26C acala per protocol prior to entering TFO; 2 additional pts had PD at C25 and EOT. Median tx duration was 19C. In univariate analyses, age, del11q, del13q, IGHV mutational status and baseline LN ≥ 5 cm were not predictive of uMRD4 at C13. At a median follow-up of 38 months, the median PFS for the overall cohort is 42 months (95% confidence interval (CI): 37, not reached), with an estimated 36-month PFS of 69% (95% CI: 57%, 84%). At data cutoff, of 46 pts entering TFO, 29 pts remained in TFO without PD, 7 pts had PD during TFO but had not met iwCLL criteria for re-tx, and 10 pts had PD requiring tx (5 pts re-tx pe protocol, 5 came off study for non-protocol tx approach). The overall median TFO period (measured from acala dc to PD) was 25 months (95% CI: 21 – not reached, n=46 pts). 5 pts have initiated re-tx with acala + O (1 pt best response PR and uMRD4; 4 ongoing tx). Median time to re-tx was 18 months (range 6-34, n=5 pts). Conclusions: This study is proof-of-concept that cBTKi may be administered as a time-limited tx without the addition of a BCL2i. While the initial PFS is shorter than historical studies examining continuous cBTKi, of patients entering TFO after 1-2 years of acala, the median duration of TFO until PD is 25 months, and longer follow-up will provide re-tx outcomes. Potential advantages to MRD-guided, time-limited cBTKi tx include time off tx for pts, limiting acquired resistance, the ability to re-challenge with cBTKi at progression, and reserving BCL2i for third-line or later tx.
Survival after first relapse of pediatric B-ALL differs by insurance type: A real-world analysis from the recall-1 study
Lind, Katherine , Berry, Abigale, Liu, Hongyan , Nguyen, Gabriella, Bhojwani, Deepa, Quigg, Troy C. , Maude, Shannon L. , Shah, Nirali, Al-Mulla, Abdulla , Ahmed, Ibrahim , Beck, Jill C., Bhatla, Deepika, Briscoe, Eliza, Chu, Roland, Davis, Laurie , Drinkwine, Jennifer, Elias, Anna , Elo, Lyannette, Eom, Elizabeth, Faulk, Kelly , Goode, Erin , Hamill, Darcy, Hammoud, Miza Salim, Hinson, Ashley , Kinoshita, Hannah , Kohorst, Mira A. , Krieger, Elizabeth , Lee‐Miller, Cathy , Milner, Jordan , Moore‐Higgs, Giselle J., Murphy, Lindsey , Murphy, Megan , Patel, Hiren P. , Prosser-Dombrowski, Alexandra, Rahrig, April , Saraf, Amanda J. , Shoag, Jamie , Symons, Heather J. , Tastet, Nicholas, Thomas, Stephanie , Thornock, Molly, Vasanna, Smitha Hosahalli, Vasco, Alejandra Escobar, Weisnicht, Allison , Zarnegar‐Lumley, Sara , Elgarten, Caitlin W. , Li, Yimei , Rubinstein, Jeremy , Fabrizio, Vanessa A , Hall, Anurekha G. , Bhojwani, Deepa , Shah, Nirali N , Ortega, Maria, Briscoe, Eliza, Dolan, J. Gregory , Hoover, Alex , McNerney, Kevin Owen , Moskop, Amy , Murphy, Megan, Patel, Hiren, Pfeiffer, Thomas , Rahim, Mahvish Qureshi , Toner, Keri , Winestone, Lena E. , Myers, Regina M.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6292-6292

10.1182/blood-2025-6292 Get It

Abstract BACKGROUND Children exposed to poverty during frontline therapy for B-lymphoblastic leukemia (B-ALL) experience inferior overall survival (OS), higher relapse rates, and earlier relapse than their peers. Real-world data describing treatment patterns and survival after relapse of B-ALL are lacking and, as a result, the impact of poverty following relapse remains poorly understood. This study evaluated the association of poverty exposure, proxied by insurance status, with post-relapse survival and explored potential explanatory mechanisms, including disease biology and therapy utilization. METHODS Data from Retrospective Study of Contemporary Approaches to First Relapse in B-ALL (ReCALL-1), a multicenter retrospective cohort study of patients < 30 years old with first relapse of B-ALL from 2018-2022, were used. The primary exposure was poverty, proxied by insurance status at relapse, categorized as any private insurance (poverty unexposed), public-only insurance (poverty exposed), no insurance, or unknown; the latter two were not included in comparative analyses due to low numbers. The primary outcome was OS. Secondary outcomes included measurable residual disease (MRD)-negative second complete remission (CR2), relapse after CR2, non-relapse mortality (NRM), with relapse treated as a competing risk, and receipt of cellular and immunotherapies. RESULTS Among 462 patients from 31 U.S. institutions, 41% had private insurance, 47% public-only insurance, 2% no insurance, and 10% unknown. Compared to privately insured patients, those with public insurance were more likely to be Hispanic (56% vs 19%, p<0.001) and have non-English preferred language (30% vs 6%, p<0.001). Non-Hispanic Black patients comprised 9% of those with public insurance and 5% of those with private insurance. Disease characteristics that differed by insurance status at relapse included: Ph-like cytogenetics, more common in publicly insured (23% vs 11%, p=0.002), and infant ALL, more common in privately insured patients (10% vs 5%, p=0.06). Publicly insured patients were more likely to have experienced major organ toxicity during frontline therapy (32% vs 18%, p=0.002) and very early relapse (<18m from diagnosis: 43% vs 32%, p=0.07). Other demographic and disease characteristics, including relapse site and cytomolecular features, were similar by insurance status. With a median follow-up of 51 months from relapse, 4-year OS differed by insurance (log-rank p=0.02): 72% for private vs 56% for public insurance. After adjusting for race/ethnicity and language, public insurance increased the hazard of death by 65% (aHR 1.65 95% CI 1.13-2.42, p=0.004). The association remained, but was attenuated, when unbalanced disease characteristics (time to relapse, infant ALL, Ph-like cytogenetics, prior organ dysfunction) were included (aHR 1.47, 95% CI 1.00-2.16, p=0.05). Rates of MRD-negative CR2 were similar (85% public vs 87% private). However, point estimates suggested publicly insured patients had more relapse after CR2 (44% vs 37%, p=0.42) and higher 4-year NRM (16% vs 10%, Gray's test p=0.12), though neither were significant. Treatment choices for first relapse did not differ by insurance status. Utilization of intensive reinduction (91% vs 95% for public vs private, p=0.18) and clinical trial enrollment (22% for both) were similar. Receipt of cellular therapies did not significantly differ by public vs private insurance: Chimeric Antigen Receptor-T cells (CAR-T: 38% vs 34%, p=0.41), hematopoietic cell transplant (HCT: 42% vs 47%, p=0.32). Use of blinatumomab trended higher in those with private insurance (36% vs 45%, p=0.07), and inotuzumab was similar (11% for both, p=0.87). Median time from relapse to CAR-T or HCT was comparable (to CAR-T 102 vs 100 days, to HCT 117 vs 114 days). CONCLUSION This is the first study to demonstrate differential survival by insurance type, a proxy for poverty exposure, after first relapse of B-ALL. In this large multicenter, real-world cohort, patients with public insurance had worse OS after relapse than those with private insurance. The survival disparity existed independent of other SDOH factors. Adjustment for known high-risk disease features only partially accounted for the observed differences in OS. In contrast, rates of MRD-negative CR2 and receipt of CAR-T and HCT were comparable across insurance types. These findings highlight the urgent need to identify effective interventions that will ensure equitable outcomes after relapse.
AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning
Corraes, Andre De Menezes Silva , Shaw, Monica , Holmes, Lucy , Burgstahler, Allison, Riester, Kimberly, Jankowski, Matthew, Hampel, Paul J. , Kapoor, Prashant , Khurana, Arushi , Kourelis, Taxiarchis , Leung, Nelson , Warsame, Rahma , Kumar, Shaji , Ansell, Stephen M. , Johnston, Patrick B. , Guzman, Emmanuel Contreras , Shaw, Monica, Holmes, Lucy, Burgstahler, Allison, Mclean, Jody, Villasboas, José C. , Bennani, N. Nora , Binder, Moritz , Gertz, Morie A. , Kenderian, Saad S. , Cook, Joselle , Shah, Meera , Alkhateeb, Hassan B. , Wang, Yucai , Durani, Urshila , Paludo, Jonas , Lin, Yi

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6131-6131

10.1182/blood-2025-6131 Get It

Abstract Introduction: CAR-T therapy has transformed cancer therapy. with its first Food and Drug Administration (FDA) approved product in August 2017. Given the expanding indications and growing experience, particularly with management of immediate toxicities requiring specialized expertise such as Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity syndrome (ICANS), FDA recently removed the Risk Evaluation and Mitigation Strategies (REMS) for CD19 and BCMA targeting CAR-T on June 26th2025. In particular, given that CRS and ICANS typically occur in the first 2 weeks post CAR-T infusion, the minimum required stay near CAR-T treatment center is reduced from one month to 2 weeks. While this could reduce treatment burden for patients (pts) who need to travel away from home to receive CAR-T, there is a need to update the transition of care from CAR-T center to pts' local oncology practice. Pts carry in their rate of recovery and have varying supportive care needs in the second half of the month post CAR-T infusion. To assist with care transition and planning, we examine the use of AI multimodal large language model (LLM) to predict patients' supportive care needs 2 weeks after CAR-T infusion based on the clinical data at the time of CAR-T evaluation, prior to leukapheresis. This timepoint was selected to also maximize travel, lodging and caregiver planning for pts and family as well. Methodology: Pts who were treated with FDA-approved CAR-T at Mayo Clinic Rochester between December 2022 and June 2025 were examined. Based on experiences with referral practices in the Midwest region, we defined patients with high monitoring needs as those who between day 14-30 post CAR-T had either hospital admission due to recurrent CRS or ICANS or required transfusion of more than 1 blood product per week (red blood cell or platelets). Others were classified as low monitoring needs. Clinical notes, labs, vital signs and electrocardiogram at the time of CAR-T evaluation were abstracted and summarized by Gemini LLM for association with patients with high versus low monitoring needs post CAR-T. Model was developed and tested for predicted needs and concordance with actual outcome of these pts. Results: Among the 362 pts who received FDA approved CAR-T in the timeframe, 84 pts had high monitoring needs. An additional 84 pts with low monitoring needs were randomly selected from 278 pts. These were divided into a training cohort and test cohort of 84 pts each, with 42 pts with high and 42 pts with low monitoring needs. Demographics of the two cohorts displayed no statistical difference. LLM analysis of the clinical data at the time of CAR-T eval identified 5 categories associated with risk for high monitoring needs: 1) Disease status (clinical notes about bulky, progressive disease or CNS involvement); 2) inflammatory and tumor burden markers (CRP, LDH); 3) hematologic status (platelet, plt; neutrophil count ANC); 4) renal function; 5) performance status. Using common clinical lab parameter convention (platelets <100, ANC< 1, CrCl< 30ml/min), and prioritizing for not missing pts with high monitoring needs, LLM model was defined to predict patients for high monitoring needs if high risk feature was identified in category 1 or any category combinations; whereas patients with no high risk feature or only 1 category that is not disease status was predicted as low monitoring needs. In this model, the sensitivity was 85.7%, specificity 23.8%, F1 score 65.5%. Applying this model to test cohort 2, the sensitivity was 83.3%, specificity 28.6%, and F1 score 65.4%. Discussion: We demonstrate proof-of-concept that LLM can be used to analyze clinical data at the time of evaluation for CAR-T eligibility to predict for supportive care needs post treatment. Not surprisingly, features identified by LLM to be associated with high monitoring needs are those previously reported by us and others at the time of CAR-T evaluation and or pre-lymphodepletion to be associated with risk for cytopenia, infection, hospitalization and non-relapse mortality. Based on the summary output generated by LLM, additional opportunities for classification methods were identified to improve specificity and balanced accuracy of the LLM model. This is a promising tool for further development to assist clinicians and patients to plan their treatment journey.
Anti-platelet factor 4 antibodies in MGUS-related thrombosis
Kanack, Adam J. , Splinter, Noah P., Mauch, Emily, Leger, Rachel, Shah, Surbhi , Kumar, Shaji , Pruthi, Rajiv K. , Padmanabhan, Anand , Houghton, Damon E. , Dispenzieri, Angela , Chen, Dong

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1321-1321

10.1182/blood-2025-1321 Get It

Abstract Introduction: Monoclonal gammopathy of thrombotic significance (MGTS) is a recently recognized thrombophilia where monoclonal platelet factor 4 (PF4)-specific IgG antibodies initiate a chronic prothrombotic state characterized by recurrent and potentially life-threatening thrombosis. Studies from large data sets demonstrate that patients with monoclonal gammopathy of undetermined significance (MGUS) have a heightened risk of experiencing thromboembolic events without a precise explanatory mechanism. The prevalence of MGTS in MGUS-related thrombosis is unknown; however, the recent identification of MGTS antibodies as a cause of thrombosis suggests a potentially causative mechanism. Emerging evidence indicates that detecting pathogenic MGTS antibodies presents diagnostic challenges due to the insensitivity of FDA-approved diagnostic assays adopted from HIT (HIT ELISAs) and gold-standard functional tests that use heparin-treated platelets, such as the serotonin release assay (SRA). Only PF4-enhanced functional assays, including the PF4-dependent P-selectin expression assay (PEA) and PF4-SRA, have proven sensitive for detecting MGTS antibodies. In this study, the PEA was utilized to better define the incidence of pathogenic anti-PF4 antibodies among a cohort of MGUS patients with a history of thrombosis. Methods: A search of the Mayo Clinic Dysproteinemia Bank was conducted to identify two cohorts of IgG MGUS patients, one with venous thromboembolism-associated diagnosis code(s) and the other without. A diagnosis of multiple myeloma was exclusionary. Each serum sample was assessed using the PEA. Mayo Clinic's Institutional Review Board approved the research study. Results: Among the 134 patients studied in the thrombosis cohort, 17 (13%) stimulated platelet activation in the PEA (positive cut-off ≥19%), some weakly. Of these, four patients (Patients 1-4) were confirmed to have PF4-dependent platelet-activating antibodies inhibitable with high concentrations of heparin and sensitive to blockade of the IgG receptor on platelets, FcGRIIa. The thrombotic complications experienced included recurrent deep venous thrombosis (DVT) over several years (Patient 1), a single DVT (Patient 2), a thrombotic cerebrovascular accident (CVA) (Patient 3), and a series of thrombotic events, including DVTs, left atrial thrombosis, pulmonary embolism, and acute limb ischemia (Patient 4). Notably, longitudinal samples spanning twelve years (Patient 1), six years (Patient 2), three years (Patient 3), and on a single sample date (Patient 4) were confirmed positive by PEA. The prolonged persistence of platelet-activating anti-PF4 antibodies in Patients 1-3 supported a diagnosis of MGTS in these patients. Strikingly, all four patients tested negative in two FDA-approved HIT ELISAs (Immucor PF4 IgG and Zymutest HIA IgG). SRA was negative for Patients 1 and 2, weakly positive for Patient 3 (33%), and positive for Patient 4 (72%). Of the 166 patients in the MGUS minus thrombosis cohort, one patient demonstrated a non-heparin induced HIT-like antibody that was HIT ELISA (Optical Density >1.0) and PEA-positive, and inhibitable using high concentrations of heparin and FcGRIIa blockade. No follow-up samples were available to assess antibody longevity. The patient had no history of thrombosis, and testing demonstrated that the anti-PF4 antibody was not synonymous with the MGUS antibody.Conclusions: Among a cohort of 134 MGUS patients with thrombosis, the prevalence of MGTS was found to be 2.2% (3 patients with persistent platelet-activating anti-PF4 antibodies). The identification of anti-PF4 antibodies among MGUS patients provides a mechanism contributing to the increased thrombotic risk associated with monoclonal gammopathies. Antibody negativity in HIT ELISA and variable positivity in the SRA highlight the nonclassical serology associated with anti-PF4 antibodies in MGTS and support performing PF4-enhanced functional testing. In addition, some patients appear to produce coincidental (non-monoclonal) platelet-activating anti-PF4 antibodies without evidence of thrombosis, although the longevity of such antibodies could not be examined in the one patient where it was identified. These findings highlight the need for larger, prospective MGUS studies to validate these observations, further define the interplay between monoclonal gammopathies and thrombotic risk, and to better understand the long-term outcomes of patients with MGTS.
Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?
Torka, Pallawi , Bock, Allison M. , Vaughn, John, Thiruvengadam, Swetha, Sekaran, Kanithra , Lee, Calvin , Smilnak, Gordon , Patel, Vrutti , Baek, Grace , Mynam, Ritwick , Sano, Dahlia , Gerber, Drew, Palmeri, Marisa, Mrad, Rudy, Sharp, John , Geethakumari, Praveen Ramakrishnan , Karimi, Yasmin , Feldman, Tatyana , Svoboda, Jakub , Shanmugasundaram, Krithika , Herrera, Alex F. , Karimi, Yasmin H , Назаренко, Елена Борисовна , Xu, Yizhe , Vaughn, John, Thiruvengadam, Swetha, Major, Ajay , Reef, Daniel K. , Luttwak, Efrat , Shah, Harsh , Ip, Andrew , Falade, Ayo , Iqbal, Madiha , Voorhees, Timothy , Rhodes, Joanna , Durani, Urshila , Cherng, Hua‐Jay J. , Pophali, Priyanka A. , Di, Mengyang , Niu, Alex , Grover, Natalie S. , Karmali, Reem , Diefenbach, Catherine , Epperla, Narendranath

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3622-3622

10.1182/blood-2025-3622 Get It

Abstract Introduction: Older adults (OAs) with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients (pts). NAVD has been widely adopted in clinical practice for frontline (1L) treatment of OAs with advanced stage cHL based on the subset analysis of S1826 study (Rutherford et al, JCO 2025) showing a 1-year progression-free survival (PFS) of 93% and 1-year overall survival (OS) of 95% after NAVD (n = 50) which remained durable on longer-term follow up. Another phase 2 study (Torka et al, JCO 2025) showed that NAVD is a highly effective and well-tolerated 1L regimen in OAs with cHL (n=40) across a wide range of geriatric impairments. Adverse events (AEs) and efficacy have not been reported in OAs treated with NAVD outside of a clinical trial. Hence, we sought to evaluate safety profile and efficacy outcomes of OAs with cHL treated with 1L NAVD in a real-world setting (RWS). Methods This is a multicenter retrospective cohort study of adults (≥18 years) with cHL treated with 1L NAVD between 2023 and 2025 at 20 US academic sites. Baseline characteristics and outcomes of pts ≥60 years were evaluated as a pre-planned subset analysis. The safety evaluable cohort received at least 1 cycle of NAVD and included pts who had not yet completed treatment. The efficacy evaluable cohort had completed 6 cycles of treatment including end of treatment (EOT) PET-CT and included pts who intended to complete treatment but died or discontinued due to progressive disease or AEs. The primary endpoint was EOT overall response rate (ORR). Secondary endpoints included EOT complete response rate (CRR), PFS and OS. PFS and OS were analyzed using the Kaplan Meier method. Results Among 311 pts, 81 were OAs (26%). Median age of the OA cohort was 70 (range 60-88) yrs, 65% male, 84% Caucasian, 71% nodular sclerosis subtype, 58% stage 4 disease, 59% B symptoms, 14% bulky disease (>7.5 cm), 69% extranodal sites, 41% EBV positive, 54% hypoalbuminemia, 49% IPS ≥ 4 and10% had an autoimmune disease. G-CSF was given in 81% pts. All 81 pts were evaluable for safety; 74% experienced a grade 3+ (≥G3) AE, 54% had ≥G3 hematological AE, 48% had ≥G3 neutropenia, 17% had febrile neutropenia. Infection rate was 28% with 10% ≥G3, neuropathy rate was 23% with 4% ≥G3. One infusion reaction was noted. Treatment related hospitalizations rate was 23% with median duration of 7 (range 1-16) days. There were 24 immune related AEs (IrAE) (30%) of which 5 were ≥G3. Most common IrAE was hypothyroidism (n=5), followed by inflammatory arthritis (n=4), pneumonitis (n=2, ≥G3, n=1), hepatitis (n=2, both ≥G3), adrenal insufficiency (n=2, ≥G3, n=1), colitis (n=2), and rash (n=2). One patient each had autoimmune neutropenia, sarcoidosis of lung/skin and myocarditis (≥G3). Overall, 15% pts required steroids with resolution of IrAEs in 56% cases, 30% (n=7) pts required continued therapy (levothyroxine in 4 pts, steroids in 3 pts, medical tx for heart failure in 1 pt). Treatment was interrupted in 22%, reduced in 22%, and discontinued in 23% pts. Nivolumab was discontinued in 14% pts. Among all pts (n=81), 81% had an interim PET-CT after 2-4 cycles. The ORR and CR rate at interim PET-CT were 100% and 81%, respectively. In the efficacy evaluable pts (n=52; 24 still on therapy), the EOT ORR and CRR were 93.2% and 84% in OAs compared to 96.8% and 91.7% in pts <60yrs, respectively. At a median follow up of 10.2 mo (range 0.27-28.52), the 1-yr PFS was 90.6% (95% CI: 82.7%-99.3%) in OAs and 95.5% (95% CI: 91.6%- 99.6%) in pts <60 yrs (p=0.044). 1-yr OS was 97.5% (95% CI: 94.1-100%) and not evaluable in pts <60yrs (p=0.017). None of the baseline features were predictive of response, additional analysis to understand impact on AEs and survival is ongoing. Among the 5 pts with progression/relapse, 4 were primary refractory. 4 pts received 2nd line (2L) therapy.79 pts are alive at data cut off, 2 deaths occurred- 1 infection-related and other unknown; both after the 1st cycle. Conclusions In this largest RWS cohort of OAs treated with NAVD we showed comparable response rates, AEs and 1-year survival outcomes to those in the pivotal S1826 trial. Notably, rates of ≥G3 AEs including infections, neuropathy and IrAEs remained low and manageable. Although survival significantly improved with NAVD compared to historical data, outcomes of OAs remained inferior compared to pts <60 yrs. Our data reinforces the use of NAVD as the preferred 1L option for OAs with advanced stage cHL.
Rural-urban disparities in survival rates in adult Hodgkin lymphoma: A population-based study
Elhusseiny, Khaled , Chen, Xuan , Hajjar, Adnan Humam, Hassan, Ibrahim , Sharief, Nourin, Shah, Jay , Hebishy, Ahmed, Hassan, Ibrahim , Mahmoud, Alaa, Sherif, Nourin Ali , Mahadevia, Himil , Mahmoud, Alaa

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3625-3625

10.1182/blood-2025-3625 Get It

Abstract Introduction Hodgkin's lymphoma is known to have favorable survival outcomes; however, limited data exist regarding survival disparities between rural and urban populations. In this study, we aimed to investigate the differences in survival outcomes between the two populations. Methods Data for patients diagnosed with Hodgkin lymphoma (HL) between 2000 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Rurality was identified using the Rural-Urban Continuum Codes (RUCC). Patients aged ≥ 20 years with HL as the only primary malignancy were included. Individuals with unknown race or those diagnosed at autopsy were excluded. The Ann Arbor Staging system was utilized for HL staging at diagnosis. HL-specific survival was defined as the time from diagnosis to death attributable to HL and was censored at the time of death from other causes or at last follow-up. Meanwhile, overall survival (OS) was defined as the time from diagnosis to death from any cause and was censored if the patient was still alive. A Cox proportional hazards model was performed to analyze the predictors for 10-year overall and HL-specific mortality. All statistical analyses were conducted using RStudio (version 2024.12.0). Results Between 2000 and 2015, a total of 22,505 patients diagnosed with Hodgkin lymphoma (HL) were included in the analysis. Among them, 13,657 (61%) were aged between 20 and 44 years. Overall, 10,137 patients (47%) were female, 14,885 (66%) were White, 2,672 (12%) were Black, and 3,724 (17%) were Hispanic. The majority of patients resided in urban counties, while only 2,266 (10.1%) lived in rural areas. Among rural patients, 845 (37%) were diagnosed with stage II disease, followed by 475 (21%) with stage III at the time of diagnosis. Notably, both the 10-year overall survival (69.5%) and Hodgkin lymphoma–specific survival (79.7%) were significantly lower among rural patients compared with urban patients (75.3% and 83.5%, respectively; p < 0.001). In the multivariable model for 10-year HL-specific survival, older age (> 65 years) was associated with the highest risk of mortality (HR 10.32; 95% CI 9.42–11.32). Although survival improved over the study period, male patients remained at increased risk of mortality (HR 1.26; 95% CI 1.18–1.35). Urban residence, diagnosis in more recent years, early stage, female sex, White race, and married status were independently associated with improved overall survival (p < 0.01). Conclusion In this population-based study, both the 10-year overall and HL-specific survival were consistently lower among rural vs. urban patients. Male sex, older age, and unmarried status were particularly associated with worse survival outcomes. Further research is warranted to identify possible strategies for improving healthcare access and reducing survival disparities among rural patients.
Real-world one-month mortality and bleeding outcomes with caplacizumab in thrombotic thrombocytopenic purpura: A propensity-matched cohort study
Chandani, Kanishka Uttam, Ilyas, Usman , Tated, Ritu C., Futela, Pragyat , Joshi, Dhruvi , Kondapally, Apoorva, Thukral, Jatin , Gopu, Sooraj Srirangadhamu , Northfelt, Donald W. , Shah, Surbhi , Kinard, Theresa N. , Williams, Lawrence, Tsang, Mazie , Hilal, Talal

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4892-4892

10.1182/blood-2025-4892 Get It

Abstract Background Thrombotic Thrombocytopenic Purpura (TTP) is a rare, typically acquired disorder due to an immune-mediated deficiency of ADAMTS13, a metalloprotease responsible for cleaving large multimers of von Willebrand Factor (vWF). In the absence of ADAMTS13 activity, ultra-large vWF multimers accumulate, promoting widespread platelet aggregation and microvascular thrombosis. This consumptive cascade leads to thrombocytopenia, microangiopathic hemolytic anemia, fever, neurological symptoms, and rarely renal dysfunction. Although therapeutic plasma exchange (TPE) has long been the cornerstone of TTP treatment, the FDA approved Caplacizumab as a first-line treatment for TTP in 2019. This drug is a bivalent single-domain antibody that binds to the A1 domain of vWF and prevents its interaction with platelets, thus effectively interrupting the pathogenic cascade, which is associated with a risk of bleeding. Methods We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, comprising data from 152 healthcare organizations. Adults (≥18 years) with a diagnosis of TTP who received Caplacizumab plus TPE were compared to patients with TTP who received TPE alone. 1:1 propensity score matching (PSM) was performed to balance characteristics between cohorts. The primary outcomes assessed were all-cause mortality and major bleeding events over a period of 1 month. Results A total of 4084 patients with TTP were identified, of whom 356 received caplacizumab with TPE and 3728 received TPE. After PSM, 2 balanced cohorts were created: C+P (Caplacizumab + TPE), P only (TPE), each comprising 356 patients. The average age in C+P and P only, after PSM, was 50.4 +/- 16.2 and 50.8 +/- 16.2 years, respectively. Females formed 65.7% of both C+P and P only, and males accounted for 28.4% and 28.7% of C+P and P only, respectively. 2.8% patients in C+P and 7.06% patients in P only had all-cause mortality at the end of 1 month. One-month all-cause mortality was significantly lower in C+P (2.8%) compared to P only (7.06%), with an odds ratio (OR) of 0.385 (95% CI 0.182 to 0.814, p=0.010). Upon assessment of bleeding outcomes, no statistically significant risk difference was noted between the 2 groups, with the odds ratio being 0.974 (95% CI 0.399 to 2.379, p=0.954). Conclusion Our large database study suggests that the addition of caplacizumab to standard TPE therapy is associated with a reduction in one-month all-cause mortality in patients with TTP, without a corresponding increase in major bleeding. However, given the lack of granular clinical data, such as contraindications to caplacizumab use, it is possible that patients who received TPE alone were inherently at a higher risk. As such, while these findings support the potential benefit of early caplacizumab use, they should be interpreted with caution and warrant prospective validation to confirm causality and assess long-term outcomes.
Incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections and cardiovascular events between chimeric antigen receptor (CAR) T-cell therapy products in multiple myeloma (MM): A nationwide analys
Mahadevia, Himil, Modi, Karnav, Shah, Raj, Modi, Shivani, Vojjala, Nikhil, Vodnala, Deepthi, Khumri, Taiyeb, Cossor, Furha, Mahadevia, Himil , Modi, Karnav, Shah, Raj, Modi, Shivani, Vojjala, Nikhil, Vodnala, Deepthi, Khumri, Taiyeb, Cossor, Furha

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6351-6351

10.1182/blood-2025-6351 Get It

Abstract Introduction: CAR T-cell therapy represents a pivotal treatment for individuals with relapsed or refractory (R/R) MM. Currently, two CAR T-cell therapeutics have received regulatory approval: Abecma (idecabtagene vicleucel, ide-cel) and Carvykti (ciltacabtagene autoleucel, cilta-cel). Although direct comparative investigations delineating the efficacy of these modalities are absent, clinical trials have shown significant disparities in response and remission rates between these therapies. Both agents are implicated in the manifestation of CRS and ICANS; however, variations in the frequency and severity of these adverse effects have been observed. We harnessed data from the National Inpatient Sample (NIS) to gain a deeper understanding of the incidence of different adverse events associated with both CAR T products in MM. Method: In this retrospective study, the 2022 NIS database was used to identify hospitalizations with MM and those who received ide-cel or cilta-cel using appropriate ICD-10-CM diagnostic and ICD-10-PCS procedure codes. Data on CRS, ICANS, infections, and adverse cardiac events were extracted using relevant ICD-10-CM codes. These outcomes were compared between the two CAR-T products using Pearson's chi-square analysis. Multivariate logistic regression was also performed, adjusting for demographics, hospital-specific characteristics, and comorbidities. Results: We identified 805 patients with MM who received CAR T-cell therapy, among whom 530 patients (60.4% male; 67% Caucasian, 14.6% African American and 17.5% other ethnicities) received ide-cel and 275 patients (70.9% male; 79.6% Caucasian, 14.3% African American and 6.1% other ethnicities) received cilta-cel. The incidence of CRS was 72.6% for ide-cel and 56.4% for cilta-cel, and the difference was almost statistically significant by chi-square analysis (p = 0.051). This difference was not statistically significant after multivariate analysis [Adjusted Odds ratio (OR) = 0.5, CI 0.2 to 1.3, p=0.154]. The incidence of ICANS was 19.8% for ide-cel and 18.2% for cilta-cel, and it was not statistically significant by chi-square analysis (p = 0.825). Among cardiovascular events, there was no significant difference in the incidence of cardiogenic shock (ide-cel vs cilta-cel, 0.9% vs 0%, p = 0.497), stroke (0.9% vs 1.8%, p = 0.661) and arrhythmias (22.6% vs 21.8%, p = 0.892) between these CAR T-cell therapies. Furthermore, there were no significant differences in the incidence of infectious complications, including pneumonia (1.9% vs 0%, p = 0.334), sepsis (0.9% vs 3.6%, p = 0.247), or septic shock (0.9% vs 0%, p = 0.430) between these CAR T-cell therapies. There was no significant difference in all-cause in-hospital mortality between these therapies (1.9% vs 5.5%, p = 0.181). Conclusion: There was no significant difference in the occurrence of CRS and ICANS between ide-cel and cilta-cel in our study. Both CAR T-cell therapies have the potential to cause infections and cardiovascular issues, necessitating careful monitoring, early detection, and timely treatment. When choosing between these CAR T-cell therapies, several factors should be considered, including the patient's previous treatment history, manufacturing time, cost, availability, and potential short-term and long-term side effects. Our study has some limitations, including its retrospective design, dependence on ICD-10 codes for identifying patients with adverse events, and the lack of long-term longitudinal data on adverse effects. However, this study provides important insights for hematologists regarding the rates of specific adverse events associated with both the CAR T-cell products in a real-world setting.
Patterns of care in second line management of nodal peripheral T-cell lymphoma from the lymphoma epidemiology of outcomes (LEO) and molecular epidemiology resource (MER) prospective cohort Study
Aperna, Fnu, Orlando, Evelyn, Ravindra, Aditya, Akkad, Neha , Moore, J. Russell, Pongas, Georgios , Kille, Kelsey, Hamid, Muhammad Saad , Mehta-Shah, Neha, Flowers, Christopher R. , Allen, Pamela B. , Ruan, Jia , Wallace, Danielle, Ravindra, Aditya , Larson, Melissa C. , Watkins, Marcus P. , Nayak, Rahul , Mehta–Shah, Neha , Malpica, Luis , Cerhan, James R. , Maurer, Matthew J. , Feldman, Andrew L. , Mou, Eric , Bennani, N. Nora

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3635-3635

10.1182/blood-2025-3635 Get It

Abstract Background Nodal peripheral T-cell lymphomas (nPTCLs) are a challenging group of non-Hodgkin lymphomas that frequently recur after or are refractory to first line (1L) treatment. Chemotherapy options in the relapsed or refractory (R/R) setting are limited. The incorporation of non-cytotoxic agents including antibody drug conjugates, immune checkpoint inhibitors, epigenetic modifiers, and phosphatidylinositol 3-kinase inhibitors offers new therapeutic potential and possibly better outcomes. We report on outcomes for patients (pts) with R/R nPTCL enrolled in the multi-center LEO-MER prospective cohort study (NCT02736357) who received second line (2L) therapy. Methods Six hundred and three adult pts with newly diagnosed nPTCL were prospectively enrolled in the University of Iowa/Mayo Clinic MER observational cohort (2002-2015) or the expanded LEO cohort (2015-2020). Secondary overall survival (sOS) was calculated from date of 2L treatment initiation to date of death or last follow-up. Secondary event-free survival (sEFS) was calculated from date of 2Ltreatment initiation to disease progression, initiation of 3rd line therapy, or death from any cause. sEFS and sOS were evaluated using Cox model and Kaplan-Meier estimator. Log-rank test was used to test the significance of difference between groups. Pts with concomitant B-cell lymphomas were excluded from this analysis. Results Thus far, 169 pts with nPTCL initiating 2L therapy were evaluated. Of these, 75 (44.4%) had PTCL-NOS, 63 (37.3%) had angioimmunoblastic T-cell lymphoma (AITL, inclusive of nodal T-follicular helper cell lymphoma), 20 (11.8%) had ALK-negative anaplastic large cell lymphoma (ALCL), and 11 (6.5%) had ALK-positive ALCL. At 2L treatment initiation, the median age was 64 with 86.1% of pts having advanced stage disease. Of the 108 pts with available international prognostic index (IPI) scoring, 46.3% had an IPI of ≥3. Thirty-four (20.1%) pts had received a consolidative autologous stem cell transplant (ASCT) in the 1L. A total of 86 pts (50.1%) had primary refractory disease (partial response, stable or progressive disease as best response to 1L therapy), 45 (26.6%) experienced early relapsing disease within 6 months of 1L therapy, and 38 (22.5%) had relapsed disease >6 months from 1L therapy. After a median follow-up of 7.1 years (yrs), median sOS was 1.52 yrs, and sEFS was 3.2 months (mos). There was no difference in sOS or sEFS regardless of timing of relapse. In keeping with other studies, ALK-positive ALCL pts had the best 5-year OS (70.1%) compared to other subgroups (ALK-negative ALCL 45.0%, AITL 30.4%; PTCL-NOS 21.3%). Lymphoma was the leading cause of death following 2L therapy, with a 2-year cumulative incidence of 49.2%. Eighty pts (47.3%) received only cytotoxic chemotherapy as second line (2L) therapy; ICE (41 (51.3%)) and gemcitabine-containing regimens were most common (14 (17.5%)). Seventy-five pts (44.4%) were treated with non-cytotoxic agents given as monotherapy or in combination with chemotherapy. The most common non-cytotoxic therapies were brentuximab vedotin (33 (44.0%)), romidepsin (17 (22.7%)) and immune checkpoint inhibitors (9 (12.0%)). Fourteen pts (8.3%) underwent palliative interventions involving radiation, steroids, or cyclosporine alone. Intent to proceed to transplant in the 2L was known in 158 pts (101 (63.9%) not intended, 57 (36.1% intended)). Following 2L treatment, 18 (10.7%) pts proceeded to consolidative ASCT and 10 (5.9%) to allogeneic transplant. Only 21 (12.9%) were treated on a clinical trial. Pts who received a non-cytotoxic agent had superior outcomes compared to pts receiving only chemotherapy; the median sOS was 30.4 mos (95% confidence interval [CI] 15.3, 53.52 mos) vs 11.7 mos ((95% CI 7.95,19.58); p=0.04; HR 0.67) and the median sEFS was 4.83 mos (95% CI 3.38, 10.09) vs 2.33 mos ((95% CI 1.71,3.02); p=0.02; HR=0.65). Conclusions We report here one of the largest prospective cohorts in R/R nPTCL. The LEO-MER cohort, despite its association with academic centers, shows poor outcomes regardless of refractory or relapsed disease, frequent inability to proceed to intended consolidative transplant, and low clinical trial participation in 2L, which corroborates findings from other registries (Jain 2025, Stuver 2019). Outcomes improved for pts treated with non-cytotoxic agents. Updated data including additional pts and subgroup analyses will be reported at the meeting.
National trends and disparities in leukemia and septicemia-related mortality in theunited states from 1999-2023: A CDC wonder database analysis
Wazir, Hakim , Reza, I M Khalid, Cherukuri, Swathi Priya , Rachakonda, S., Shah, Khushbakht, Chauhan, Anchit , Amjad, Amna, Nawaz, Shaheen, Inam, Noora, Mulk, Yassar Ul, Nimmagadda, Rithish , Tummala, Nayanika, Fernandes, Bolivia , Imankhah, Reza , Shah, Khushbakht, Nawaz, Shaheen

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6933-6933

10.1182/blood-2025-6933 Get It

Abstract Background: Leukemia, a type of cancer of the blood forming tissues, compromises the immune system putting the body at risk of aggressive infections like septicemia. This can not only progress to septic shock but also death. The occurrence of the two conditions makes it almost necessary to understand the epidemiological patterns to increase the rates of survival. This study assesses the trends in mortality in patients with leukemia and septicemia in the United States from 1999-2023. Methods : We analyzed death certificates of adults aged 5 to 84 years' from the CDC-WONDER database with Leukemia (ICD-10 codes: C91, C92) and Septicemia (ICD-10 codes: A40, A41) from 1999-2023. Age-adjusted mortality rates (AAMR) per 100,000 population were stratified by gender, race, census region, year and age. Join-Point analysis was performed to estimate annual percent change (APC) and average annual percent change (AAPC) in mortality trends, along with 95% confidence intervals (CIs). Results : Between 1999 and 2023, Leukemia and Septicemia caused 56,497 deaths in patients aged 5 to 84 years. The total AAMR decreased from 0.78 in 1999 to 0.66 in 2023. Demographically, AAMR among the men decreased significantly from 1.04 to 0.85 (AAPC: -0.65; 95% CI: -0.80 to -0.49). Females experienced a decline in mortality from 0.59 to 0.46(AAPC: -0.44; 95% CI: -0.71 to -0.17). In terms of race, a slight decrease in mortality was witnessed in the mortality of Non-Hispanic (NH) Black or African Americans from 0.91 to 0.7 (AAPC:-1.13 ; 95% CI: -1.43 to -0.82), moreover the AAMR in the Hispanics decreased from 0.8 to 0.63 (AAPC: -0.04; 95% CI: -0.04 to -0.58) while those among the white community decreased from 0.78 to 0.68 (AAPC: -0.39; 95% CI: -0.58 to -0.19). Moreover, the Asian community also experienced a declining death rate. Geographically, regions in the Midwest showed the highest overall AAMR (0.75), followed by the West,Northeast and areas in the South with an overall AAMR of 0.72 . Between the urban and rural areas, rural areas had a higher AAMR as compared to the urban areas with an overall AAMR of 0.17. When stratified according to states, AAMRs varied highly from the highest in Kentucky (0.89) to the lowest in Maine(0.26). Conclusion: The overall mortality rates for leukemia and septicemia decreased between the years 1999-2023. The greatest change was seen in males, regions in the Northeast, racially in NH Blacks and the rural areas.